(2,5-Dioxofuran-3-yl)methyl acetate | 860374-03-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2,5-Dioxofuran-3-yl)methyl acetate
• CAS: 860374-03-4
• 化学式: C₇H₆O₅
• 分子量: 170.122
• InChiKey: XTVURKVYEIUFNM-UHFFFAOYSA-N

物化性质

• 沸点：
  295.7±23.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2,5-Dioxofuran-3-yl)methyl acetate 在 哌啶 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 17.0h， 生成 acetic acid 2-(5-methylfuran-2-ylmethylene)-5-oxo-2,5-dihydrofuran-3-ylmethyl ester
  参考文献：
  名称：

  A facile chemoenzymatic approach to natural cytotoxic ellipsoidone A and natural ellipsoidone B

  摘要：

  Starting from citraconic anhydride (3) a facile four-step synthesis of deoxyellipsoidone 8 has been reported with 37% overall yield. An elegant six-step access to naturally occurring cytotoxic ellipsoidone A (1) and ellipsoidone B (2) has been reported with good overall yields, via the conversion of itaconic anhydride (9) to the acetoxymethylmaleic anhydride (11), regioselective sodium borohydride reduction of anhydride 11 to acetoxymethylbutyrolactone 12, Knoevenagel condensation of lactone 12 with 5-methylfurfural, selenium dioxide induced oxidation of the formed butenolide 13 and an Amano PS catalyzed deacylation of the formed diacetoxybutenolide 14 as a pathway. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.12.020
• 作为产物：
  描述：

  柠康酸酐 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 5.0h， 生成 (2,5-Dioxofuran-3-yl)methyl acetate
  参考文献：
  名称：

  一种脂肪类碘鎓盐及其制备方法和应用

  摘要：

  本发明属于光刻胶技术领域，具体涉及一种脂肪类碘鎓盐及其制备方法和应用。所述碘鎓盐具有如下式所示结构： 且该碘鎓盐不带有芳香结构，且紧邻环状结构的碘鎓盐，作为光刻胶光致产酸剂，其具有较短的吸收波长(低于200nm)，能够适用于ArF(193nm)和KrF(248nm)光刻胶的应用；且该碘鎓盐中碘紧邻环状结构，因环张力会有利于碘鎓盐的分解，从而能够提高光效率和光活性。

  公开号：

  CN115536668A

文献信息

• [EN] COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES<br/>[FR] COMPOSÉ APPROPRIÉ POUR LE TRAITEMENT DE SYNUCLÉOPATHIES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2011084642A1

  公开（公告）日：2011-07-14

  The present invention relates to a compound of formula (I): Wherein R1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt. I

  本发明涉及一种化合物，其化学式为（I）：其中R1是取代或未取代的芳香杂环或同环基，或取代或未取代的脂环杂环基；R2是具有1至18个碳原子的烷基基团或取代或未取代的环烷基或芳基；R3是取代或未取代的芳香杂环或同环基，或取代或未取代的脂环杂环基；L是单键，具有1至6个碳原子的烷基基团，NHCO，O，S，NHCONH或NHCOO；X、Y和Z分别为0、N、NH、S或CH；W是单键或具有1至6个碳原子的烷基基团；或其药学上可接受的盐或所述化合物或盐的药学上可接受的溶剂。
• Compound Suitable for the Treatment of Synucleopathies
  申请人：Masliah Eliezer

  公开号：US20130035342A1

  公开（公告）日：2013-02-07

  The present invention relates to a compound of formula (I): Wherein R 1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R 2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R 3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt.

  本发明涉及一种式为（I）的化合物：其中，R1是取代或未取代的芳香杂环或同环或取代或未取代的脂环杂环或同环基团；R2是1至18个碳原子的烷基基团或取代或未取代的环烷基或芳基基团；R3是取代或未取代的芳香杂环或同环或取代或未取代的脂环杂环或同环基团；L是单键、具有1至6个碳原子的烷基基团、NHCO、O、S、NHCONH或NHCOO；X、Y和Z独立地为0、N、NH、S或CH；W是单键或具有1至6个碳原子的烷基基团；或其药学上可接受的盐或该化合物或盐的药学上可接受的溶剂化物。
• COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES
  申请人：Neuropore Therapies, Inc.

  公开号：US20140364610A1

  公开（公告）日：2014-12-11

  The present invention relates to certain heteroaromatic compounds of Formula (Ia), or pharmaceutically acceptable salts thereof, and uses of such compounds in the treatment of synucleopathies.

  本发明涉及公式（Ia）的某些杂环芳香化合物，或其药学上可接受的盐，并且涉及在治疗突触核病中使用此类化合物的用途。
• US8846682B2
  申请人：——

  公开号：US8846682B2

  公开（公告）日：2014-09-30
• A facile chemoenzymatic approach to natural cytotoxic ellipsoidone A and natural ellipsoidone B
  作者：Sanjib Gogoi、Narshinha P. Argade

  DOI：10.1016/j.tet.2005.12.020

  日期：2006.3

  Starting from citraconic anhydride (3) a facile four-step synthesis of deoxyellipsoidone 8 has been reported with 37% overall yield. An elegant six-step access to naturally occurring cytotoxic ellipsoidone A (1) and ellipsoidone B (2) has been reported with good overall yields, via the conversion of itaconic anhydride (9) to the acetoxymethylmaleic anhydride (11), regioselective sodium borohydride reduction of anhydride 11 to acetoxymethylbutyrolactone 12, Knoevenagel condensation of lactone 12 with 5-methylfurfural, selenium dioxide induced oxidation of the formed butenolide 13 and an Amano PS catalyzed deacylation of the formed diacetoxybutenolide 14 as a pathway. (c) 2005 Elsevier Ltd. All rights reserved.